Table 1 Patient characteristics
From: Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report
Treatment | |||||
|---|---|---|---|---|---|
Total | Stupp | HFRT + TMZ | HFRT | p | |
Number of patients | 104 | 33 (32%) | 37 (35%) | 34 (33%) | |
Gender | 0.65 | ||||
Male | 53 (51%) | 19 (58%) | 18 (49%) | 16 (47%) | |
Female | 51 (49%) | 14 (42%) | 19 (51%) | 18 (53%) | |
Age | <0.01* | ||||
Median (years) | 75 [70–88] | 73 [70–81] | 75 [70–80] | 79 [70–88] | |
< 75.5 years | 55 (53%) | 24 (73%) | 20 (54%) | 11 (32%) | |
≥ 75.5 years | 49 (47%) | 9 (27%) | 17 (46%) | 23 (68%) | |
KPS | <0.01* | ||||
Median | 70 [30–100] | 80 [50–100] | 70 [30–100] | 60 [40–90] | |
KPS < 70 | 40 (38%) | 5 (15%) | 13 (35%) | 22 (65%) | |
KPS ≥ 70 | 64 (62%) | 28 (85%) | 24 (65%) | 12 (35%) | |
Type of suregery | 0.09 | ||||
Resection (complete/ partial) | 5 / 9 (5% / 9%) | 2 / 6 (6% / 18%) | 1 / 2 (3% / 5%) | 2 / 1 (6% / 3%) | |
Biopsy | 90 (86%) | 25 (76%) | 34 (92%) | 31 (91%) | |
MGMT status | 0.58 | ||||
Methylated | 33 (45%) | 11 (41%) | 12 (43%) | 10 (56%) | |
Unmethylated | 40 (55%) | 16 (59%) | 16 (57%) | 8 (44%) | |
Unknown | 31 | 6 | 9 | 16 | |
RPA Class | <0.001* | ||||
I-II | 14 (14%) | 8 (24%) | 3 (8%) | 3 (9%) | |
III | 52 (50%) | 20 (61%) | 22 (59%) | 10 (29%) | |
IV | 38 (36%) | 5 (15%) | 12 (32%) | 21 (62%) | |
Adjuvant Temozolomide | 28 (27%) | 18 (55%) | 10 (10%) | 0 (0%) | <0.0001* |
Treatment at recurrence | 12 (12%) | 7 (21%) | 3 (8%) | 2 (6%) | 0.1 |